Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

2w ago Venture Capital Cannabis greenmarketreport Views: 216

-

Havn Life Sciences (CSE: HAVN) (OTC: HAVLF) is looking to restructure after reporting it will not be able to pay off its debt without newfound coin.

“There is no assurance that the restructuring will be successful or that the company will be able to secure a new source of financing,” Havn said in a news release.

The Canadian psychedelics research company said that it is actively trying to find funds to support continuing operations.

The news comes as the psychedelic sector continues to swing amid a cooldown in the broader economy and regulatory inertia by federal lawmakers.

Havn originally planned to develop a library of psychoactive compounds designed to support a standardized psychedelics supply chain that researchers could use for clinical trials.

In 2020, Health Canada gave the company permission to possess certain amounts of psilocybin for the research and development of quality control methods. The green light also allowed the company to diversify its venture and manufacture natural health products.

-

However, turning promise into profit has not been so easy.

In the past year, the company has forgone M&A deals and kept waving red flags to investors when it chose to issue a 30-1 reverse split in July to beef up its stock and get private placement.

Havn also finalized C$9 million worth of debt financing to cover its cash burn despite the company having a C$1 million market cap. The company cannot issue more monthly convertible debentures if it would result in the investor owning more than 10% of the company.

Havn reported gross profit of C$89,700 for the last fiscal year but a gross loss of C$22 million, nearly half of which was directly attributable to operations, according to regulatory filings.

Havn Life Sciences Faces Bankruptcy, Cash Crunch Cuts Runway on Green Market Report.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.